OpenAI Rolls Out ChatGPT Health, Claims Clinician-Level Reasoning
SkimNews Take
When one OpenAI executive claims clinical-level reasoning that a colleague won't publicly endorse, it signals to healthcare buyers that marketing outpaces validated capability — potentially slowing the enterprise adoption the consumer rollout is designed to accelerate.
Get the Tech newsletter
Daily tech — startups, AI labs, chips, the launches that shape the next decade. Free.
- OpenAI is rolling out ChatGPT Health to all US users on Thursday, allowing them to connect medical records and health-tracking data to the chatbot and ask questions about it directly in the main chat experience.
- Ashley Alexander, OpenAI's VP of health product, claimed the company's models "are now capable of reasoning at levels that are better than clinician level."
- Karan Singhal, OpenAI's health lead, tempered the claim in the same briefing, saying he would "temper" it and pointing to "individual studies" — including one from Harvard and Stanford — that are "pointing in that direction."
- A Florida pastor sued OpenAI on Wednesday, alleging ChatGPT provided "extremely dangerous medical recommendations" that led him to delay care for a pulmonary embolism.
- ChatGPT Health runs on GPT-5.6 Sol, which OpenAI calls its "strongest model yet for health" and launched weeks earlier, and integrates data from health providers and apps including Apple Health, Weight Watchers, MyFitnessPal, and Function.
- OpenAI says health conversations are "encrypted at rest and at transit" with additional encryption in Health, and the platform is rolling out to all logged-in users aged 18+ across free, Go, Plus, and Pro plans on web and iOS, with the caveat that it "supports, not replaces, professional care."
Why it matters: OpenAI's own health lead walked back his VP's 'better than clinician level' boast in the same briefing, on the same day a Florida pastor sued over allegedly dangerous medical advice — exposing the gap between OpenAI's marketing for ChatGPT Health and the legal and clinical reality it faces as it opens medical data tools to every US adult.
